Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Midazolam

FDA-approved product (spray, nasal), marketed as Midazolam In 0.8% Sodium Chloride, Midazolam In 0.9% Sodium Chloride, Nayzilam and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Midazolam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amnesia
  • Epilepsy
  • Seizure
  • Status epilepticus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Midazolam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Midazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

    NCT01071304 · start 2010-03

    Registered record
    Registry ID
    NCT01071304
    Conditions
    Relapsed or Refractory Advanced Cancer
    Interventions
    Midazolam; Ridaforolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Advanced Cancer
    InterventionMidazolam; Ridaforolimus
    PhasePhase 1
    Registry statusCompleted

  • The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy

    NCT01027715 · start 2010-01

    Registered record
    Registry ID
    NCT01027715
    Conditions
    Seizures; Encephalopathy
    Interventions
    EEG monitoring and treatment of EEG seizures
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2015-12
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeizures; Encephalopathy
    InterventionEEG monitoring and treatment of EEG seizures
    PhaseNot applicable
    Registry statusCompleted

  • Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

    NCT00809146 · start 2009-06

    Registered record
    Registry ID
    NCT00809146
    Conditions
    Status Epilepticus
    Interventions
    Intramuscular route of active treatment; Intravenous route of active treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-01
    Enrolment
    1,023

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStatus Epilepticus
    InterventionIntramuscular route of active treatment; Intravenous route of active treatment
    PhasePhase 3
    Registry statusCompleted

  • HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects

    NCT00410254 · start 2007-06

    Registered record
    Registry ID
    NCT00410254
    Conditions
    Healthy
    Interventions
    HCV-796; midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-06
    Completion
    2007-08
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionHCV-796; midazolam
    PhasePhase 1
    Registry statusCompleted

  • A GameBoy as a Distraction Before Surgery in Children

    NCT00176670 · start 2004-01

    Registered record
    Registry ID
    NCT00176670
    Conditions
    Anxiety
    Interventions
    midazolam or GameBoy or parental presence
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-01
    Completion
    2006-04
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety
    Interventionmidazolam or GameBoy or parental presence
    PhasePhase 2
    Registry statusCompleted